ANA.AQSE

Ananda Developments Plc
Ananda Developments - Presenting at Aquis Showcase
4th November 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6483K
Ananda Developments PLC
04 November 2024
 

4 November 2024

 

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

 

Presentation at Aquis Showcase

 

Ananda Developments plc (AQSE: ANA), a Company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is pleased to announce that it will be presenting at the Aquis Stock Exchange Showcase on Tuesday 12th November in London, at the Royal College of Surgeons, WC2A 3PE.

 

Finance Director Jeremy Sturgess-Smith will deliver an eight-minute pitch, followed by a rapid-fire Q&A session to a live investor audience.

 

The event will provide an  opportunity to hear directly from the management team on the Company's pharmaceutical product development plans and to connect with them in person.

 

Investors interested in attending can register here with the code 'AQ20'.

 

-Ends-

To stay abreast of the latest developments at Ananda, follow our social media channels at:  

  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

  

-Ends-  

  

The Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA DEVELOPMENTS PLC 

+44 (0)7463 686 497 


ir@anandadevelopments.com 

Chief Executive Officer 


Melissa Sturgess 




Finance Director 


Jeremy Sturgess-Smith 




SP ANGEL CORPORATE FINANCE LLP 

+44 (0)20 3470 0470 



Corporate Finance 


Richard Morrison 






Corporate Broking 


Abigail Wayne 


Rob Rees 

 


 

Yellow Jersey PR (media enquiries)

Sarah MacLeod

Charles Goodwin

Zara McKinlay

 

+44 (0)20 3004 9512

ananda@yellowjerseypr.com

 

 

About Ananda Developments  

  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

   

https://investors.anandadevelopments.com/link/5PmQqP

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZMGMMMFGDZM]]>
TwitterFacebookLinkedIn